OR WAIT null SECS
September 17, 2021
Both Comirnaty, Spikevax jabs had previously been authorized for use under Interim Order
September 16, 2021
Deal is dependent on FDA approval of Phathom’s vonoprazan compound
Availability of space for new labs is a key selling point
September 15, 2021
Acquisition expected to help provide customers with a quicker clinical trial recruitment process
Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot
September 14, 2021
Expansion at German facility features new GMP manufacturing lines and a cleanroom, among other additions
September 13, 2021
Latest construction plan continues CDMO’s vision for biopharma expansion
FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance
September 10, 2021
Biotech firm to file regulatory dossier with officials around the world
September 09, 2021
CDMO’s objective is to cater to various market segments in order to meet microbial bio-manufactured compound demand
